Precisely how SSRIs induce long-term modifications in serotonin transmission to elicit their antidepressant actions is unclear. In this issue of Neuron, Issler et al. (2014) identify a key role for microRNA-135a in the raphe nuclei in the molecular mechanisms underlying the therapeutic actions of SSRIs.
Serotonin-selective reuptake inhibitors (SSRIs) are the current first-line treatment for major depressive disorder (MDD) and other mood disorders including generalized anxiety disorder (GAD). SSRIs bind to the serotonin transporter (SERT) and thereby inhibit the clearance of serotonin (5-HT) from the synaptic cleft. This triggers a complex cascade of signaling events that ultimately results in downregulation of SERT and also serotonin 1A (5-HT1A) autoreceptors on serotonergic neurons in the raphe nuclei (RN). In turn, these adaptive responses increase serotonergic neuronal firing and elevate extracellular levels of 5-HT in terminal brain regions such as the hippocampus and prefrontal cortex (PFC), an action considered critical to the therapeutic effects of SSRIs. However, the mechanisms by which chronic SSRI treatment downregulate SERT and 5-HT1A receptor levels to induce long-lasting alterations in serotonergic transmission are unclear.
Evidence suggests a role for altered patterns of gene expression in mediating the long-term therapeutic effects of SSRIs. Much interest has focused recently on the potential involvement of microRNA-mediated regulation of gene expression in this process. MicroRNAs (miRNAs) are small noncoding RNAs that bind to the 3 0 UTR of target mRNAs, causing mRNA destabilization and/or translational inhibition (Bartel, 2009) . MicroRNAs have widespread roles in the physiology of the CNS (Mehler and Mattick, 2007; O'Carroll and Schaefer, 2013) . Furthermore, microRNAs are implicated in a range of psychiatric disorders (Mellios and Sur, 2012; Miller and Wahlestedt, 2010) , including anxiety and depression (Hansen and Obrietan, 2013; O'Connor et al., 2012; Serafini et al., 2014) . Recent findings have also increased interest in the potential involvement of microRNAs in antidepressant drug action. In particular, it was shown recently that miR-16 targets SERT and may contribute to the actions of SSRIs (Baudry et al., 2010) . Further, miR-1202 is a primate-specific miRNA associated with MDD and responsiveness to SSRIs (Lopez et al., 2014) . In this issue of Neuron, Issler et al. (2014) provide compelling evidence further implicate microRNAs in the pathophysiology of depression and in regulating the actions of SSRIs.
As serotonergic neurons of the dorsal raphe nucleus (DRN) are implicated in depression and SSRI action, Issler et al. (2014) first investigated the microRNA expression profile of 5-HT neurons in this brain region by taking advantage of a mouse line that expresses the fluorescent protein YFP specifically in serotonergic neurons. Fluorescence cell sorting generated two neuronal populations from the embryonic DRN: YFP-positive 5-HT neurons and nonfluorescent cells including inhibitory neurons and glia. The miRNA profile of 5-HT versus non-5-HT cells was compared, and those with at least a 2-fold difference in expression in either group were chosen for further analysis. Of these miRNAs, miR-135, was of particular interest as its expression was relatively lower in the 5-HT neuron population, suggesting that it could potentially contribute to the phenotype of these cells. Moreover, gene transcripts predicted to be targeted by this microRNA included SERT (Slc6a4) and the 5-HT1A autoreceptor (Htr1a). Consistent with these predictions, miR-135a and its ortholog miR-135b were shown to substantially downregulate expression of a luciferase reporter conjugated to the 3 0 UTR of Slc6a4 or Htr1a. Mutation of the putative binding site for miR-135 in these 3 0 UTRs abrogated miRNA repression, suggesting that these transcripts are indeed direct targets of miR-135.
Of the two miR-135 alleles found in mice, miR-135a is more highly expressed in adult mouse DRN than miR-135b. Because both miR-135a and antidepressant treatment negatively regulate expression of SERT and 5-HT1A, Issler et al. (2014) next investigated whether miR-135a levels are altered in a mouse model of depression or after antidepressant administration and can thereby influence mood. Chronic social defeat, in which mice are exposed to long-term aggressive behavior from another mouse, can induce some depression-related behaviors that respond to antidepressants (Russo and Nestler, 2013) . These behaviors include social avoidance, anhedonia, and anxiety-like behaviors. While chronic social defeat per se did not alter miR135a levels, acute or chronic treatment with the tricyclic antidepressant imipramine or the SSRI fluoxetine increased miR-135a expression in the raphe nuclei in control mice and in mice that had undergone social defeat. By contrast, the noradrenaline reuptake inhibitor antidepressant drug reboxetine did not alter miR-135a levels, suggesting that miR135a expression is preferentially sensitive to serotonergic transmission.
To investigate the function of miR-135a in serotonergic neurons in vivo, Issler et al. (2014) generated a Cre-dependent miR135a overexpressing mouse line that was bred with mice expressing Cre specifically in serotonergic neurons. In agreement with the luciferase assays, levels of SERT and 5-HT1A were decreased at the mRNA and protein level in the miR-135a-overexpressing mice. Because decreased expression of these genes is thought to underlie their antidepressant effects of SSRIs, it was hypothesized that miR-135a could contribute to their mechanism of action. Consistent with this possibility, miR-135a overexpression enhanced the resilience of mice to chronic social defeat. This was reflected by the fact that anxiety-and depression-like behaviors were detected in the elevated plus-maze, dark-light emergence test and forced swim test in wild-type mice but not in miR-135a overexpressing mice. There was also an increase in serotonin turnover in key brain regions implicated in depression in the overexpressing mice including the hippocampus and PFC. Moreover, viral-mediated knockdown of miR-135a in raphe resulted in increased expression levels of SERT and 5-HT1A and increased anxiety-like behaviors. Interestingly, miR-135a knockdown attenuated the efficacy of an SSRI to reduce immobility in the forced swim task consistent with SSRIs acting at least in part through miR-135a. It is interesting to note that previous studies have found that approximately one-third of mice are resilient to the negative affective consequences of chronic social defeat stress. Hence, it will be interesting to determine whether endogenous miR135a levels are relatively higher in those mice shown to have a resilience phenotype or lower in those that demonstrate increased vulnerability to depression-like behaviors.
These findings suggest that upregulation of miR-135a in the raphe contributes to the therapeutic actions of SSRIs, but these findings are based on observations in rodents. Depression is notoriously difficult to model in rodents because of complex and unclear origins, its highly heterogeneous symptoms, and the inability to determine whether such core symptoms as sadness and even suicidality can be manifest in rodents. Therefore, to investigate whether their findings may extend to depression in human subjects, Issler et al. (2014) next assessed miR-135a levels in the brains of depressed human patients who had committed suicide. Consistent with a role for miR-135a in the disorder, it was found that levels of the miRNA were decreased in the raphe nuclei of suicide victims. Circulating levels of miR-135a were also lower in the plasma of depressed patients, suggesting that this microRNA could serve as a diagnostic and perhaps even prognostic biomarker for the disorder.
These intriguing findings provide further support for the involvement of miRNAs in MDD and the mechanism of action of antidepressant drugs. Important future questions include identifying precisely which neurons express miR-135a in adults, as the neuronal subtype expressing endogenous miR-135a in adult was not examined. Also, the molecular and behavioral consequences of miR-135a overexpression do suggest a predominantly serotonergic function; however, a direct or indirect role in other cell types such as noradrenergic neurons, which also express SERT, cannot be ruled out. Indeed, SSRI treatment differentially regulates miR-16, which also targets SERT, in noradrenergic and serotonergic populations in the locus coeruleus and dorsal raphe nucleus, respectively. The signaling pathway causing miR-135a upregulation downstream of SSRI action remains unclear, but an analysis of transcription factor binding sites in the promoter of miR-135a could shed light on potential mechanisms. SSRI-mediated induction of miR-135a expression could be a secondary consequence of increased extracellular 5HT levels and subsequent activation of 5-HT1A receptors. Perhaps miR-135 acts endogenously in a homeostatic mechanism that ensures the correct balance of 5-HT1A receptors and SERT expression. This could be explored in the future by selectively manipulating the activation or levels of Htr1a and observing whether this in itself can alter miR-135a expression.
